Research Reports

Key takeaways

Revenue increased 1559% to $244K, reflecting expansion in native staking rewards and HAUS agreement fees supporting Hyperliquid validator operations.

Gross profit rose 1565% to $244K with 100% margins, as cost of revenue aligned closely with topline growth from DeFi activities.

Net income reached $8.8M versus -$3.5M prior year (354% change), with diluted EPS at $0.26 compared to -$1.59, marking profitability inflection.

Net cash from operations was -$4.2M, similar to -$4.4M last year, as non-cash gains reversed and working capital needs persisted despite income growth.

Ophthalmology-related expenses declined due to layoffs following CHAPERONE study termination and commercial slowdown.

Full analysis

Legacy ophthalmology operations continued winding down, with expense decreases from reduced salaries, benefits, and non-cash stock compensation following CHAPERONE study termination and commercial slowdown. Hyperliquid remains the principal market for HYPE valuation, selected for highest volume, accessibility, and orderly transactions with 70-millisecond block times.

Management views existing resources as sufficient for anticipated operations through one year from the May 15, 2026 filing, based on current financial condition and cash flow forecasts. However, continued pursuit of at-the-market equity offerings carries no assurances of availability or acceptable terms, underscoring reliance on digital asset volatility and capital markets for sustainability amid cash burn.

HYPD · Hyperion DeFi, Inc.

Summary

Key takeaways

Full analysis